Wednesday, July 8, 2026

biotech · Attention Deficit Hyperactivity Disorder · Vascular Ehlers-Danlos Syndrome · AYTU

AYTU BIOPHARMA

AYTU BIOPHARMA clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Denver, USA HQ
2015 Founded
105 Employees
Public company Type
AYTU · NYSE Ticker
Company details
Status
Public
HQ
Denver, USA
Founded
2015
Employees
105
Programs
3
Drugs
5
Patents
4
Intelligence · Clinical Programs

AYTU BIOPHARMA projects

3 ClinicalTrials.gov programs sponsored by AYTU BIOPHARMA.

AYTU BIOPHARMA has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Enzastaurin

    AYTU BIOPHARMA, INC

    Vascular Ehlers-Danlos Syndrome

    phase 3 small molecule on hold

    1 trial
  2. ADZENYS XR-ODT

    AYTU BIOPHARMA, INC

    Attention Deficit Hyperactivity Disorder

    approved small molecule terminated

    1 trial
  3. Antioxidant

    AYTU BIOPHARMA, INC

    Compare the sORP Rate in Sperm Samples, Obtained by the Mioxsys System, Before and After 2.5 Months Antioxidant Men Supplements Treatment (Fertybiotic Man)

    other terminated

    1 trial

Frequently asked questions

How many clinical projects does AYTU BIOPHARMA have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.